Scholar Rock, Inc.
Clinical trials sponsored by Scholar Rock, Inc., explained in plain language.
A biopharmaceutical company developing therapies targeting growth factors for neuromuscular and other diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug aims to build muscle in rare muscular dystrophy
Disease control Recruiting nowThis Phase 2 study tests a drug called apitegromab in 60 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes muscle weakness. Participants will receive either the drug or a placebo every 4 weeks for a year. The main goal is to see if the dru…
Phase: PHASE2 • Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug hopes to boost muscle power in babies with SMA
Disease control Recruiting nowThis study tests a drug called apitegromab in children under 2 years old who have spinal muscular atrophy (SMA), a genetic condition that causes muscle weakness. The drug works by blocking a protein that limits muscle growth. Researchers want to see if adding apitegromab to stand…
Phase: PHASE2 • Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug SRK-439 tested for safety in healthy adults
Knowledge-focused Recruiting nowThis Phase 1 trial is testing the safety and tolerability of a new drug called SRK-439 in 76 healthy adults aged 18 to 55. Participants receive either a single or multiple doses of the drug or a placebo by injection. The study measures side effects, lab tests, and how the drug mo…
Phase: PHASE1 • Sponsor: Scholar Rock, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC